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CC BY-NC-ND license (http://creativeAbstract Activating and inactivating mutations in numerous human G protein-coupled recep-
tors (GPCRs) are associated with a wide range of disease phenotypes. Here we use several class
A GPCRs with a particularly large set of identified disease-associated mutations, many of which
were biochemically characterized, along with known GPCR structures and current models of
GPCR activation, to understand the molecular mechanisms yielding pathological phenotypes.
Based on this mechanistic understanding we also propose different therapeutic approaches,
both conventional, using small molecule ligands, and novel, involving gene therapy.
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by-nc-nd/4.0/).Introduction
Seven transmembrane domain architecture of G protein-
coupled receptors (GPCRs) appeared very early in evolution.
Striking structural similarity between a group of photopig-
ments from bacteria and archaebacteria on the one hand,
and rhodopsins and related GPCRs from eukaryotes on the
other, is often cited as an example of convergent evolution.
However, recent demonstration that the order of helices can
be scrambled in sequence and the resulting protein still
forms functional photopigment1 suggests that all prokaryotic
and eukaryotic rhodopsins evolved from a common ancestor,rev ich@vanderb i l t .edu
ity of Chongqing Medical
015.02.005
ng Medical University. Production
commons.org/licenses/by-nc-nd/even though this happened so long ago that sequence ho-
mology cannot be traced. Animals have more GPCR subtypes
than other groups of living organisms. The genomes of pri-
mates (including humans) and bats have at least 800 GPCRs,2
whereas other mammals have a lot more, with elephants
expressing >3,200 GPCR subtypes currently holding the re-
cord (sevens.cbrc.jp/). Thus, it is pretty clear that GPCR
design was a huge evolutionary success.3 Here using several
well-studied class A (rhodopsin-like) human GPCRs we
analyze why this particular protein architecture happened
to be so suitable for transmembrane signaling, what are the
functional consequences of various mutations in these re-
ceptors, how molecular errors translate into disease phe-
notypes, and what can be done to treat or cure genetic
disorders associated with GPCR mutations.
The key feature that makes GPCRs particularly good
signal transducers is their flexibility.4 Every protein mole-
cule is a lot more flexible than crystal structures imply,and hosting by Elsevier B.V. This is an open access article under the
4.0/).
Mutations in GPCRs 109exploring numerous conformations in physiological condi-
tions. Special feature of GPCRs appears to be that they
have several energy minima that are not dramatically
different, and relatively low energy barriers between these
conformational states.4 The affinity of many endogenous
agonists is relatively low, with KDs varying from 0.1 to
10 mM. There is a simple relationship between the inter-
action energy and affinity: DG0 Z RTlnKA, where DG0 is
free energy of association, R is a gas constant, T is tem-
perature Kelvin, and KA is association constant; it is the
inverse of equilibrium dissociation constant, KA Z 1/KD.
The calculation shows that interaction energy of these
compounds at physiological temperature is w7e10 kcal/
mol. This is certainly insufficient to push the receptor from
one state to another, suggesting that ligands essentially act
by conformational selection. In simple terms, flexible
GPCRs exist in equilibrium of many conformations. By
preferentially binding to “active” ones agonists shift the
equilibrium towards activation, whereas inverse agonists
preferentially bind “inactive” states, pushing the equilib-
rium in the opposite direction. The only obvious exception
that cannot work by conformational selection is light re-
ceptor rhodopsin.5 In the dark it has covalently linked 11-
cis-retinal, which acts as an inverse agonist. The photon
of light isomerizes 11-cis to all-trans-retinal, which acts as
an agonist, while remaining covalently bound. Structural
similarity of rhodopsin to other receptors, first discovered
after sequencing of b2-adrenergic receptor,
6 which lead to
the concept of GPCRs, suggests that the mechanisms of
activation are likely similar in this super-family. Interest-
ingly, the energy of a photon with wavelength of 500 nm
(the peak of rhodopsin absorption) is much greater,
w57 kcal/mol, which might be sufficient to “push”
rhodopsin into the active state. Even though every protein
explores pretty wide conformational space and exists in a
multitude of conformations, for the purposes of this review
we will refer to all states that are unfavorable for G protein
binding as inactive (R), and all states that can couple to G
proteins as “active” (R*). We would like the reader to keep
in mind that in reality this long-established tradition,
however convenient, is a gross over-simplification.
Classification of GPCR mutations
Mutations altering GPCR function are usually classified ac-
cording to the net change in signaling ability. A general
decrease in relevant signaling is termed loss of function
(LOF), a general increase as gain of function (GOF).
Considering the complexity of the GPCR signaling process,
the simple discrimination between LOF and GOF does not
fully reflect the variety of disease-causing mutations. More
detailed mechanism-based classification helps to under-
stand receptor malfunctions and devise appropriate
therapy.
Mutations affecting GPCR basal activity
As GPCRs are very flexible, there is a definite probability for
the receptor to adopt an active R* conformation even
without agonist binding. This probability and the level of so
called constitutive or basal activity varies highly amongwild type (WT) GPCRs (for extensive list see7) and has
physiological importance in many cases. The melanocortin-
4-receptor (MC4R) exhibits a fairly high basal activity,
which appears to be essential for the maintenance of
normal energy homeostasis.8,9 Loss of MC4R constitutive
activity is associated with the risk of obesity.9 Both de-
creases and increases in constitutive activity can lead to
disease phenotypes.
It is believed that the level of basal activity is deter-
mined by intra-molecular constrains,10,11 which limit the
GPCR flexibility, and the ability of the receptor to adopt a
conformation in which it can activate G-protein even
without agonist binding. In many GPCRs Asp(6.30) and
Arg(3.50) form the so called “ionic lock”, a salt bridge,
which has been associated with modulation of basal activ-
ity.12 Mutation of Asp(6.30) into a variety of different amino
acids breaks this salt bridge, relieving the constraint,
thereby increasing constitutive activity in several
GPCRs.1316 In glycoprotein hormone receptors the
conserved residue Asp(6.44) was shown to play an essential
role in dampening basal activity.17 Substitutions of
Asp(6.44) lead to increased basal activity in the thyroid
stimulating hormone receptor (TSHR)18 and the luteinizing
hormone/chorionic gonadotropin receptor (LHCGR).19 The
active conformation made more probable by those muta-
tions does not always have to be identical to the one sta-
bilized by agonists. In fact, there are mutations, which
increase basal activity, but impair agonist stimulation. In
the TSHR those mutations are scattered all over the re-
ceptor structure, and their effects range from total loss to
slight decrease in TSH response, along with increased
constitutive activity. A decrease in constitutive activity
would be expected to reflect limited conformational flexi-
bility of the receptor, e.g., when the mutation introduces
additional intra-molecular constraints. In reality most mu-
tations decreasing basal activity also cause other defects,
such as impaired G protein coupling, impaired agonist
binding, or general decrease in response to agonist
simulation.Mutations affecting ligand binding
At the level of ligand binding, a mutation can change the
response by altering: (1) agonist affinity, (2) efficacy, or (3)
receptor selectivity. 1. Although altering binding affinity
does not change maximum response, it influences the EC50
value. The concentration at which a response is achieved is
either decreased (in GOF mutants) or increased (in LOF
mutants). Residues essential for agonist binding, directly
and indirectly, can be found within the extracellular re-
ceptor elements and in the trans-membrane domains, and
are expected to be involved in affinity modulation.10,20 2. A
mutation increasing the efficacy of a ligand can do so by
facilitating the formation of active receptor conformation,
which, when stabilized by agonist binding, provides a more
favorable interface for G-protein activation. In this case an
agonist would induce a stronger response while retaining
the same affinity. 3. As far as the specificity is concerned,
the glycoprotein hormone receptors provide a perfect
example. The substantial sequence homology of the three
receptors (TSHR, follicle-stimulating hormone receptor
110 H. Stoy, V.V. Gurevich(FSHR), LHCGR) and their cognate agonists (TSH, FSH, LH
and hCG) requires an exact specificity barrier.10 Mutations
broadening receptor specificity have been found both in the
large N-terminal ectodomain and within the serpentine
trans-membrane (TM) domain. The mechanisms that alter
specificity appear to be different in these two cases. Site-
directed mutagenesis suggests that substitutions within
the N-terminal ectodomain of the glycoprotein hormone
receptors alter the recognition specificity and the accessi-
bility of the receptor.20,21 Mutations within the TM domain
are expected to change the energy barrier for activation by
an alternative ligand, thereby altering functional selec-
tivity of the receptor. In case of the FSHR both types of
mutations have been associated with a defect known as
spontaneous ovarian hyper-stimulation syndrome (sOHSS).
sOHSS is the result of FSHR stimulation by elevated serum
hCG levels during pregnancy, while the receptor retains
normal ability to respond to FSH. This promiscuous response
leads to overstimulation of the ovaries despite normal
levels of FSH.10
Mutations affecting GPCR-G protein interaction
Upon GPCR activation, the cytoplasmic ends of the trans-
membrane helices V and VI move considerably to form an
interface for G-protein binding and activation.22,23 G-pro-
tein binding residues are mainly located within helices III, V
and VI.20 Mutations can interfere with the process of
coupling to downstream effectors by altering the exposure
or the structure of the interaction interface. Experimen-
tally this would also increase the affinity of the ago-
nistereceptor interaction. It should be mentioned that
many GPCRs have the ability to interact with several
different downstream effectors, such as different G-pro-
teins or arrestins. Consequently there is the possibility of a
mutation influencing the signaling outcome by a changed
bias. In most cases, functional characterization of disease-
causing mutations has been limited to determining cAMP
and IP3 levels, both of which are mediated by G-proteins.
Possible effects of those mutations on arrestin-mediated
signaling are only beginning to be unraveled. Recent
structure of the GPCR complex with arrestin24 is the first
step to understanding of the structural basis of mutation-
induced bias.
Mutations affecting cell surface expression
The discussion above was based on the assumption that
mutations do not significantly affect receptor biosynthesis
and trafficking. In reality, impaired receptor expression is
the most common defect.25 While receptor biosynthesis
does not seem to be affected in most cases, the critical
point in trafficking of mutant receptors appears to be the
ER, where the first quality control mechanism ensures that
misfolded receptors are not allowed to move to the Golgi,
but are instead trafficked to lysosomes and degraded.26,27
Several molecular defects can lead to misfolding, ranging
from the inability to bind necessary chaperones due to
missing interaction sequences to general receptor insta-
bility. Any disruption of the disulfide bridge between TM3
(C3.25) and the extracellular loop by a mutation has beenreported to lead to receptor instability and malfunction.20
Sometimes misfolding can be prevented by the application
of pharmacological chaperones, as has been shown
experimentally for several different diseases caused by
GPCR mutations.26,27 Another cause of faulty trafficking is
the disruption or deletion of signaling motifs. A motif
within the C-terminal tail of glycoprotein hormone re-
ceptor has been suggested to be essential for plasma
membrane targeting. Mutation of several residues in this
motif leads to intracellular retention.28 Many of the re-
ceptor defects discussed above, both GOF and LOF, are
often combined with a general decrease in cell surface
expression. In fact, partial intracellular retention appears
to be a general characteristic of GOF mutations. Consid-
ering the increased flexibility leading to the enhanced
signaling in the first place, it is conceivable that excessive
flexibility increases the chance of unfolding and/or
misfolding.
Frequent combination of several defects makes a
detailed functional characterization and the identification
of the ultimate cause of receptor malfunction difficult.
Nevertheless, extensive studies of the glycoprotein hor-
mone receptors, the melanocortin-4 receptor and the
vasopressin V2 receptor provide insights about structural
basis of disease-causing effects of many mutations.
GPCR mutations in diseases
GPCR malfunctions due to mutations have been associated
with many diseases, including immunological, metabolic
and reproductive disorders, cancer and neurodegenera-
tive diseases,29 but only a fraction of disease-associated
GPCR mutations have been characterized functionally
(Tables 1e3; Supplemental Table S1). For a detailed
analysis of structure-function relationships of disease-
causing mutations here we chose five most intensively
studied GPCRs: three glycoprotein hormone receptors
(GPHR), TSHR (thyroid stimulating hormone receptor),
LHCGR (luteinizing hormone/choriogonadotropin recep-
tor) and FSHR (follicle stimulating hormone receptor), the
melanocortin receptor MC4R and the V2R (arginine vaso-
pressin type 2 receptor).
The glycoprotein hormone receptors
All three GPHRs function in the endocrine system. Their
cognate ligands are produced by the anterior pituitary
gland, secreted into the bloodstream, and transported to
their target organ. Upon binding to their receptors, the
glycoprotein hormones initiate their response mainly via GS
protein, although at high ligand concentrations the GPHRs
were shown to activate the Gq/11 proteins as well. Muta-
tions in GPHRs are responsible for a variety of diseases:
activating mutations generally cause ligand-independent
activity of the target tissue, giving rise to classical hyper-
phenotypes and in some cases initiate tumor develop-
ment. Inactivating mutations result in tissue resistance to
the agonist and classical hypo-phenotypes. While GOF mu-
tations are generally dominant (Table 1a), LOF mutations
follow mainly an autosomal or X-linked recessive trans-
mission pattern (Table 1b). The presence of dominant-
Table 1a Basal Activity (GOF).
Receptor BW Mutation Size Charge Hydrophicity Ref.
TSHR 1.49 G/ S Increased More hydrophilic 19,152
MC4R 1.49 E/ K / þ 153
TSHR LHCGR 2.43 M/ T Decreased More hydrophilic 19,59,154
19,60,155,156
TSHR 3.43 L/ Q Increased More hydrophilic 25,157
TSHR LHCGR 3.43 L/ R Increased More hydrophilic 19,63
19,64,74
TSHR 5.54 V/ F Increased 158
TSHR 5.54 V/ L Increased 159
LHCGR 5.54 I/ L 14,19
TSHR, FSHR 6.30 D/ G Decreased / neutral 13,19,160,161
15,19
LHCGR, FSHR 6.30 D/ N / neutral 14,19
19,162e164
TSHR 6.34 A/ I Increased 13,19,160
TSHR, LHCGR 6.34 A/ V Increased 19,160,161,165,166
19,167
TSHR 6.34 A/ F Increased 62
TSHR, LHCGR 6.37 M/ I Decreased 19,168
19,169
TSHR, LHCGR 6.38 A/ V Increased 170
19,171
TSHR 6.40 L/ F Increased 18,19,61
TSHR, MC4R 6.40 L/ Q Increased More hydrophilic 18,19,61
19,46,48,172,173
TSHR 6.41 I/ M Increased 174
TSHR, LHCGR 6.41 I/ L 19,175
19,176
TSHR, LHCGR 6.43 T/ I Increased More hydrophobic 19,161,177e179
19,169
TSHR 6.44 D/ A Decreased / neutral 18,19
TSHR, LHCGR 6.44 D/ E Increased 18,19,178,179
19,180
TSHR, LHCGR 6.44 D/ Y Increased / neutral 18,19,161,178,179,181
14,19,36
LHCGR 6.44 D/ G Decreased / neutral 19,182,183
LHCGR 6.44 D/ H / þ 19,36
Mutations in GPCRs 111negative effects is unclear in many cases. It appears that
those effects are more likely linked to receptor biosyn-
thesis and trafficking to the cell surface than receptor
function.Table 1b Basal activity (LOF).
Receptor BW Mutation Ref.
MC4R 1.57 I/ T 48,153
MC4R 2.62 I/ S,T 19,25,173,184,185
16,19,25,48,186
MC4R 3.24 I/ T 45
MC4R 3.53 T/ I 48
MC4R 4.41 R/ W 25,45,48,172,173,184
MC4R 4.50 W/ C 95
MC4R 6.34 A/ E 45,184
MC4R 6.42 G/ S 45,48,185
MC4R 6.61 C/ R 25,173,187
MC4R 7.52 I/ T 48,172Activation of TSHR by its cognate agonist thyroid-
stimulating hormone (TSH) is essential for thyroid cell
proliferation and differentiation and stimulates the syn-
thesis and secretion of thyroid hormones.25 The thyroid
hormones, T3 and T4, exert stimulatory effects on meta-
bolism. Both GOF and LOF of the TSHR have been associ-
ated with various thyroid diseases. The physiological and
pathological aspects of TSHR signaling have been reviewed
comprehensively.30e32 Constitutive activation of the TSHR
by GOF mutations generally results in genetic non-
autoimmune hyper-thyroidism, defined by excessive
release of thyroid hormones. Somatic GOF mutations,
originally affecting only a single thyrocyte cell, result in the
formation of a benign, well defined and encapsulated ad-
enoma, demonstrating both unregulated growth and
autonomous hyperfunction.33 The tumor progressively
takes over the function of the thyroid tissue ultimately
leading to thyrotoxicosis, characterized by elevated plasma
T3 and/or T4 levels.30 Although a similar effect can be
achieved by defects within other components of the cAMP
Table 2 Transduction ability.
Receptor BW Mutation Ref.
G protein
binding pocket
V2R 3.50 R/ H 73
MC4R 3.53 T/ I 48
LHCGR 6.34 A/ V 167
FSHR 6.36 R/ C 188
LHCGR 7.55 I/ K 25,74,189
Central cluster MC4R 2.50 D/ N 190
V2R 2.50 D/ N 191e193
MC4R 3.40 I/ T 194
LHCGR 3.43 L/ R 64
MC4R 6.43 V/ I 172,184,195
LHCGR 6.45 C/ R 14
TSHR 7.45 N/ S 196
V2R 7.50 P/ S 75
Cluster helices
I and II
V2R 1.39 L/ F 197
LHCGR 1.41 L/ P 198
MC4R 1.43 G/ D 153
MC4R 1.43 G/ V 153
FSHR 2.61 A/ T 199
MC4R 2.62 I/ S 184
Outliners MC4R 4.51 A/ T 49,195
LHCGR 6.59 A/ P 76
112 H. Stoy, V.V. Gurevichcascade, activating TSHR mutations are responsible for
70%e80% of all toxic adenomas.32 Germline GOF mutations
make the whole thyroid tissue autonomous (insensitive to
regulation), ultimately resulting in hereditary toxic thyroid
hyperplasia (HTTH, also known as familial non-autoimmune
hyperthyroidism), which is an autosomal dominant disor-
der.30 In the case of spontaneous germline GOF mutations
the condition is known as sporadic congenital non-
autoimmune hyperthyroidism; patients generally tend to
display a more severe phenotype than patients sufferingTable 3 Ligand binding affinity.
GOF: Decreased KD
Receptor Mutation BW Ref.
LHCGR M/ T 2.43 19,60,155,156
TSHR M/ V 2.53 19,200
TSHR S/ R 3.36 19,160,196
TSHR V/ A 3.40 19,160,202,203
TSHR Y/ N 5.58 19,204
TSHR D/ G 6.30 13,19,160
TSHR A/ I,V 6.34 13,19,160,165,166
MC4R L/ Q 6.40 19,46,48,172,173
TSHR L/ F 6.40 18,19,61
TSHR I/ M 6.41 174
TSHR F/ L 6.42 19,211
TSHR T/ I 6.43 19,178,179
TSHR C/ W 6.47 212
MC4R F/ S 6.51 95
MC4R I/ T 7.52 48,172from HTTH.32 For an extensive summary of clinical aspects
for all three conditions see He´brant et al (2011).32 While
somatic LOF mutations remain asymptomatic, germline LOF
mutations cause resistance to TSH, resulting either in
euthyroid hyperthyrotropinemia or hypothyroidism,
depending on the severity of the mutation. Euthyroid
hyperthyrotropinemia remains mainly asymptomatic. Only
TSH plasma levels are chronically elevated to compensate
for the loss in TSHR sensitivity and to maintain T3/T4 levels
within the physiological range.34 This condition is therefore
also termed compensated hypothyroidism. More severe LOF
mutations result in congenital hypothyroidism with hypo-
plasia of the thyroid glands, but TSHR mutations appear to
be causative only in a small proportion of patients.30
Both LH and FSH are released from the anterior pituitary
gland upon stimulation by the gonadotropin-releasing hor-
mone and in turn regulate gonadal development and func-
tion via their cognate receptors, LHCGR and FSHR,
respectively. Defects of both receptors have therefore
been associated with various reproductive diseases.
Importantly, the impact of mutated receptor varies be-
tween genders.
Being expressed on the Leydig cells, LHCGR stimulates
testosterone production, which is required for male sex
differentiation. In females, LHCGR is expressed on theca
and granulosa cells, where it influences the ovarian cycle.
In males, constitutive activation of LHCGR results in a
precocious development of sexual characteristics due to
LH-independent production of testosterone at an early age,
a condition termed familial male-limited precocious pu-
berty (FMPP). Asp578Gly represents the most frequent
mutation, causing 76% of all FMPP cases.35 Interestingly,
patients suffering from FMPP display normal reproductive
function as adults.19 GOF mutations were also suspected to
be responsible for Leydig cell tumor development, but to
our knowledge only one mutation has been reported to
induce tumor development.36 In females, the constitutive
activation of LHCGR remains asymptomatic due to the
necessity of both LH and FSH for female gonadalLOF: Increased KD
Receptor Mutation BW Ref.
MC4R E/ K 1.49 153
MC4R N/ S 1.50 25,49,173,184,201
MC4R N/ D 2.57 25,49,173,195
MC4R L/ P 2.66 25,173,201
V2R R/ W 3.26 192,205e208
MC4R I/ K 3.28 25,49,173,185,195
MC4R I/ T 3.40 25,172,173,194
V2R Y/ C 5.39 191,208e210
V2R P/ H 7.50 75
Mutations in GPCRs 113development. LHCGR LOF mutations were reported to
cause Leydig cell hypoplasia in males. Depending on the
residual activity of the mutant receptor, patients display
phenotypes ranging from micropenis (in case of certain
residual activity) to complete pseudohermaphroditism (in
case of total loss of function), accompanied by an ambig-
uous phenotype.37 In females, LOF mutations result in
hypergonadotrophic hypogonadism and primary amenor-
rhea, but do not affect follicular development. Symptoms
are generally mild and present with a late onset.35
FSHR is expressed on the granulosa cells of growing
follicles in females. Stimulation by FSH is absolutely
required for normal female gonadal development, matu-
ration and function. Subsequently, LOF mutations lead to
various degrees of gonadal malfunction, ranging from
ovarian dysgenesis (ODG), to primary and secondary
amenorrhea. Again, the residual activity of the FSHR
correlates with the severity of the phenotype, a knockout
of the FSHR gene was shown to result in complete infer-
tility in female mice.38 The first and most prominent LOF
mutation was identified in a Finnish female patient with
ODG.39 Since GOF mutations in TSHR and LHCGR are
associated with tumor development, FSHR, which also
mediates cell proliferation, was expected to be respon-
sible for granulose cell tumor. Analysis never confirmed
this hypothesis. Instead, all FSHR GOF mutations identi-
fied so far are associated with ovarian hyperstimulation
syndrome (OHSS), which, as mentioned earlier, results
from a relaxation of specificity borders. In males, FSHR is
expressed on testicular Sertoli cells. Although spermato-
genesis can be initiated without FSH, FSH action appears
to be important for viability and mobility of sperm.38 LOF
mutations in males therefore lead to small testes with
various degrees of impaired spermatogenesis but do not
result in complete azoospermia.40 Only two GOF mutation
were reported in male patients. The first mutation,
Asp567Gly, was discovered in a hypophysectomized and
hypogonadotrophic male, who remained fertile with only
testosterone treatment. The second mutation remained
asymptomatic.41The melanocortin-4 receptor
The melanocortin-4 receptor (MC4R) belongs to a subfamily
consisting of five receptors, which respond to several ago-
nists (a-MSH, b-MSH, g-MSH and ACTH) and two endogenous
inverse agonists (Agouti and Agouti-related protein (AgRP)).
The MC4R is mainly expressed in neurons in brain regions
associated with feeding behavior and food intake. As part
of the melanocortin circuit, MC4R is involved in the regu-
lation of energy homeostasis. Leptin, secreted into the
blood proportionally to the amount of body fat, stimulates
the production of proopiomelanocortin (POMC), a precursor
of several active neuropeptides. POMC is cleaved to a-MSH,
which exerts an anorexigenic effect via stimulation of
MC4R. At the same time, leptin inhibits the biosynthesis of
AgRP, which normally exerts an orexigenic effect by func-
tioning as an inverse agonist to the MC4R.42 Animal studies
provided further evidence about the effects of these li-
gands: a-MSH stimulation decreases,43 while AgRP increases
weight gain.44 Any disruption of this circuit can be expectedto cause a metabolic disease, termed obesity. Generally
obesity is defined as the chronic imbalance between food
intake and energy expenditure, resulting in excessive lipid
accumulation and an increased body mass index (>30).
Although obesity is believed to be a multifactorial disease,
with both environmental and genetic factors contributing
to its severity, MC4R mutations have been suggested to
cause a monogenic form of obesity. MC4R mutations have
variable prevalence, with between 0.5% and 6% of severe
obese adults reported as carriers of MC4R mutations.42
Indeed, more than 100 mutations, both LOF and GOF have
been reported, covering 32% of MC4R residues. While LOF
mutations are associated with excessive weight gain
(obesity), GOF mutations were expected to cause an
especially lean or anorexic phenotype. Interestingly, most
of the GOF mutations reported so far were discovered in
obese subjects.45e48 Their modes of action have not been
elucidated yet. Most LOF mutants are retained intracellu-
larly,25 others have been reported to display decreased
basal activity. Since MC4R basal activity is believed to
provide a constant tonic signal of satiety, a decrease results
in increased weight gain.9 A correlation between residual
activity and severity of the phenotype can be observed.49 In
contrast to many other GPCRs, MC4R LOF mutations display
an autosomal dominant transmission pattern. Both haplo-
insufficiency and dominant negative effects due to dimer-
ization have been proposed as pathogenic mechanism.42
Physiology and pathology of MC4R have been reviewed
comprehensively recently.42,50 The MC3R has also been
associated with energy homeostasis, but, in contrast to
MC4R, its contribution to obesity is controversial.The arginine vasopressin type 2 receptor
The arginine vasopressin type 2 receptor (V2R) belongs to a
group of three receptors, all responding to the neurohy-
pophyseal nonapeptide arginine-vasopressin (AVP), but
differing in expression patterns, downstream signaling
pathways and ultimate functions. V2R is expressed in
several tissues, ranging from the kidney to the inner ear,
with its function remaining elusive in many cases. In the
kidney, V2R action has been studied extensively. There V2R
is expressed on the basolateral membrane of the collecting
ducts cells, mediating diuresis. Upon activation by AVP, V2R
exerts its effect via the stimulatory G protein pathway,
resulting in increased cytoplasmic cAMP levels and subse-
quent activation of protein kinase A (PKA). PKA in turn
mediates the insertion of the water channel aquaporin-2
(AQP2) into the luminal plasma membrane, increasing
water permeability. In addition, PKA elevates urea perme-
ability and stimulates sodium retention.27,51 Over 190 V2R
mutations, both LOF and GOF, have been reported over the
last years. LOF generally leads to the inability to concen-
trate urine despite normal levels of AVP, known as neph-
rogenic diabetes insipidus (NDI). Clinically NDI is
characterized by polyuria, polydipsia, hyposthenuria. Since
the V2R gene is located on the X-chromosome, this form of
NDI is considered as X-linked NDI (XNDI). XNDI is generally a
rare disease with about 90% of XNDI patients being males.27
GOF mutations have been reported in patients with a con-
dition known as nephrogenic syndrome of inappropriate
Figure 1 Characterization of mutations according to net change in signaling ability. Disease-causing mutations, reported in any
of the five chosen receptors (TSHR, LHCGR, FSHR, MC4R, V2R), were characterized according to the net change in signaling ability.
For direct comparison, the mutations were converted according to the BallesteroseWeinstein (BW) numbering scheme53: each
residue is given an identifier, consisting two numbers. The first identifies the helix, the second corresponds to the position of the
residue relative to the most conserved residue within this helix; the most conserved residue is assigned the number 50. To visualize
the mutations, we chose the crystal structure of the b2-adrenoreceptor (b2AR), which was numbered according to an advanced
numbering scheme, taking into account helical irregularities (can be accessed at http://tools.gpcr.org/docs/numbering). Loss of
function (A) and gain of function (B) mutations, reported in more than one receptor, are mapped separately on the b2AR structure
and depicted both in side view (left panels) and top view (right panels; as seen from the extracellular side; the ECL2 helix was
deleted for better visualization). C. Positions where mutations were reported to cause LOF or GOF, depending on the substituting
amino acid, are shown in orange in both the inactive (left) and active (right) b2AR crystal structure. The area containing most of the
mutations partially bridges the common ligand binding pocket (dark blue) and the common G protein interface (turquois), both
defined by Venkatakrishnan et al (2013).20 Black arrows within the active structure indicate which helical regions undergo major
movements during activation. The numbers of trans-membrane helices IeVII are indicated in gray circles.
114 H. Stoy, V.V. Gurevichantidiuresis (NSIAD), the inability to excrete excessive
water, resulting in hyponatremia, hypo-osmolality and
natriuresis. Only a few GOF have been reported to date.52Mutations affecting GPCR signaling
For analysis of disease-causing mutations, we focused on
the extended trans-membrane region, including the ele-
ments responsible for ligand binding, signal transduction
and G-protein coupling. Although different receptors withinthe class A GPCR sub-family show low sequence identity,
the trans-membrane part shows the highest homology in
their sequence. The BallesteroseWeinstein numbering
scheme53 allows comparison of equivalent residues in
different receptors, which otherwise show very little
sequence homology.
The intracellular and extracellular loops are regions of
high variance, both in sequence and in secondary structure,
complicating direct comparison of different receptors.
While the extracellular structures regulate ligand speci-
ficity, ligand pocket accessibility and, in the case of the
Mutations in GPCRs 115GPHR, even ligand binding, the intracellular parts have
been mainly associated with G-protein binding, receptor
desensitization and internalization. Despite the undeniable
functional importance of both regions, we will primarily
focus on mutations located within the trans-membrane part
(Tables 1e3).
To analyze the location and the structural influence of
mutations, we visualized all mutations on the backbone of
inactive and active structure of b2AR (PDB ID 2RH1 and
3SN6). We ask the reader to keep in mind that the analyzed
receptors may differ significantly both in sequence and
structure from the b2AR. Therefore, proposed ideas do not
necessarily apply to all GPCRs.Characterization of mutations according to the net
change in signaling ability
We mapped disease-causing mutations on the inactive
structure of b2AR, according to their net change in signaling
ability. LOF mutations appear to be scattered all over the
receptor structure without a clear pattern. If we focus on
mutations observed in at least two different receptors, this
decreases the number of LOF mutations drastically and
reveals their predominant localization in two main clusters:
a) at the interfaces of helices I, II and VII, and b) at the
interface between helices III and VI (Fig. 1A). GOF are also
mainly limited to the helical interfaces, further restrictions
only slightly change this picture. Interestingly, the locali-
zation of GOF is generally similar to that of LOF mutations,
but GOF mutations appear more concentrated in the cluster
around helix VI (Fig. 1B).Key residues affecting GPCR functions are clustered
at the helical interfaces
The residues where mutations can cause either LOF or
GOF appear to function as switches, which when mutated
determine the fate of the receptor. The area where these
key residues are located partially bridges a common
ligand binding pocket and common G-protein interaction
site (identified on the basis of the comparison of active
and inactive crystal structures of several different re-
ceptors20), without affecting these key areas themselves.
Comparison of active and inactive structures reveals that
these residues are mainly located in areas, which undergo
major activation-induced movements (Fig. 1C). Especially
interesting are the residues along helix VI, which experi-
ences the most dramatic structural change. The clusters
between helix III and VI and between helix VI and VII are
located around the kink area of helix VI, suggesting their
involvement in movement regulation. It is expected that
many of these residues are also involved in modulation of
basal activity or general signaling ability.
Both clusters of key residues mainly have hydrophobic
side chains in the WT sequence, which presumably stabilize
the helical organization via hydrophobic interactions. Tight
packing in this area is necessary for a functional receptor,
so that any substitutions here can be expected to lead to
instability and functional changes.Mutational alteration of GPCR basal activity
GPCR signal transduction
The mechanism of GPCR activation has been the subject of
intensive investigation, and the crystal structures eluci-
dated over the past 10 years are finally beginning to shed
some light on the complex process of receptor activation.
The comparison of receptor structures in active and inac-
tive conformation suggests that the signal is transduced
from a common ligand-binding pocket to a common G-
protein docking interface via a conserved mechanism.20
The variety of GPCR-induced responses was expected to
be reflected by the complexity of activation mechanism.
Since little is known about the specific features of this
mechanism in most receptors, here we focus on elucidated
conserved structures and the mechanisms proposed so far.
GPCRs bind a variety of different ligands, ranging from
ions and nucleotides to small molecule hormones, peptides,
and proteins. Despite this variety, Venkatakrishnan et al
suggested the existence of a common ligand-binding
pocket, deep within the trans-membrane bundle.20 This
ligand-binding pocket contains certain trigger residues,
sensing the presence of a ligand. The conserved CWxP
motif, located near the extracellular end of helix VI, is one
of these triggers. Upon ligand binding, Trp6.48 experiences
a slight shift, thereby inducing a conformational change in
helix VI, which is amplified by a proline-induced kink. Water
cluster within the ligand-binding pocket was proposed to
stabilize a non-proline kink of helix III by interacting with
Ile3.28 and Val3.32. Upon activation helix III straightens,
probably due to rearrangement of water cluster triggered
by ligand binding.54 Both ligand-activated triggers lead to
large-scale rearrangements of the trans-membrane struc-
ture, culminating in the opening of a cytoplasmic cavity
between helices III, V and VI. These large-scale changes are
accompanied by rotameric changes within conserved micro-
switches, which stabilize the active conformation. The D/
ERY motif in helix III is one of the most conserved structural
motifs in class A GPCRs, with 96% conservation for the
central Arg3.50. Both Asp3.49 and Arg3.50 stabilize the
inactive conformation by forming a number of possible in-
teractions: Asp3.49 interacts with a conserved Tyr in IL2,
tethering the loop to the helical bundle. Arg3.50 forms a
salt bridge with Asp/Glu6.30, connecting the cytoplasmic
ends of helices III and VI, thereby closing the cavity. This so
called ionic lock is not conserved in all GPCRs. In some
receptors Arg3.50 appears to participate in hydrogen
bonding with polar residues in helix VI.55 In addition,
Arg3.50 and Asp3.49 were also reported to interact elec-
trostatically.56 Upon activation, Arg3.50 experiences a
rotameric conformational change and interacts with the C-
terminal helix of Ga.23 The comparison of crystal structures
of GPCRs in different active conformations suggests that
the rotameric change of Arg3.50 requires the presence of
Ga.55 A similarly conserved motif, NPxxY, is located near
the cytoplasmic end of helix VII. Tyr7.53 functions as one of
the main activation switches: upon activation, Tyr7.53
changes its orientation towards the middle axis of the he-
lical bundle, forming new interactions, for example with
Tyr5.58 in rhodopsin and the b2AR. In GPHR this activation
switch is controlled by signature motif within helix VI, the
116 H. Stoy, V.V. GurevichFTD motif. In the inactive conformation, Asp6.44 of the FTD
motif likely interacts with the Asn7.49 of the NPxxY motif,
thereby sequestering the Arg7.49 from other interactions.
Upon activation, helix VI experiences both a rotation and a
translocation, breaking this interaction. Asn7.49 is now free
to establish new interactions, thereby stabilizing the active
conformation. Mutagenesis experiments show that muta-
tion of any of these two residues leads to constitutive
activity.17
Over the past years another aspect of GPCR activation
has developed: the idea of fine-tuning GPCR function by
allosteric modulators. A high-resolution crystal structure of
A2A-adrenoreceptor revealed internal water molecules,
forming a continuous water channel within a central cavity,
which binds a sodium ion as allosteric modulator. The water
channel was suggested to be involved in receptor activa-
tion: while the inactive structure shows the continuous
water channel, the active structure reveals two hydro-
phobic layers, disrupting the channel and decreasing the
size of the cavity from 200 A3 to 70 A3, thus releasing the
sodium ion.54 Molecular dynamic simulations have sug-
gested an opposite mechanism.57 In any case, residues
lining the channel, especially within the cavity, can be
expected to affect receptor activation if mutated. Because
of this contradiction, we will not consider the concept of
allosteric modulation further.
Potential mechanisms altering basal activity of GPCRs
An increase in basal activity requires a mutation that leads
to a ligand-independent opening of the G-protein-binding
cavity. This conformational change can be induced muta-
tionally in multiple ways. Keeping in mind the mechanism
of receptor activation by the ligand binding, it is conceiv-
able that a mutation partially mimics this process by
affecting key positions, such as ligand-dependent trigger
residues, micro-switches, or residues directly involved in G-
protein interaction. Such mutations could be identified by
simple comparison to reported common receptor elements
involved in activation. It is also generally believed that the
receptor is maintained in an inactive conformation by
restraining interactions. Releasing those constraints would
consequently lead to increased ligand-independent acti-
vation. Another possibility is mutations in positions main-
taining general receptor stability. Increased flexibility can
obviate the necessity for ligand binding to open the
G protein-binding cavity. Such mutations can be localized
everywhere within the helical bundle, where they loosen
up inter-helical interactions and therefore increase the
conformational flexibility of the receptor.
Mutations that enhance basal activity by increasing the
accessibility of the G-protein interaction site
Mapping the residues, mutations of which were reported to
increase basal activity, reveals significant overlap with
positions of mutations causing general GOF, suggesting that
an increase in basal activity is an important disease-causing
mechanism. These mutations are mainly concentrated on
the cytoplasmic half of the interfaces of helices III, V and VI
(Fig. 2B). A central cluster of residues from all three helices
is located close to the proline-induced kink in helix VI.
Additional mutations are located all along the cytoplasmic
half of helix VI. In contrast to general GOF mutations, thesecond cluster detected between helices I, II and VII is
absent in this group of mutations.
Analysis of chemical changes introduced by particular
mutations allows us to hypothesize how these mutations
increase basal activity. Considering mutation-induced
changes in size, charge and hydrophobicity of the side
chain (Table 1), we propose three possible mechanisms.
1. One powerful driving force of general protein folding
is the “hydrophobic collapse”, the assembly of hydrophobic
side chains within the core of the protein to minimize water
contacts.58 This applies to GPCRs: the structural and func-
tional integrity of the trans-membrane domain largely de-
pends on the stabilizing effect of hydrophobic contacts on
the helical interfaces. By increasing the hydrophilicity of
the side chains within the helical bundle, a mutation can
destabilize the receptor. The introduced side chain would
not fit into hydrophobic tightly packed helical bundle,
thereby not only loosening the hydrophobic core, but also
introducing major structural changes within the seven
trans-membrane domain. Ultimately this change can lead
to the opening of the cytoplasmic cavity. Mutation of a
conserved hydrophobic Met2.43 into polar Thr was shown to
increase basal activity in both TSHR59 and LHCGR.60 As part
of helix II, Met2.43 points inward and likely establishes
extensive hydrophobic contacts with residues in close
proximity (<5A). Introduced Thr would disrupt this packing
(Fig. 2C). However, it is important to keep in mind that the
exact orientation and therefore the definite interactions
might vary between the b2AR, which carries an Ile in this
position, and the GPHR. Fig. 2C only shows a likely scenario
of what Met2.43Thr mutation causes within the GPHR.
2. In a tightly packed helical core, the size of the side
chains matters. Increasing the sizemay result in clashes with
surrounding side chains, which would require small confor-
mational changes in the immediate surrounding structures
to accommodate the new side chain. This is particularly
important around the kink area of helix VI, where a small
conformational change is sufficient to turn the helix and
open up the cavity. For example, Leu6.40Phe is an activating
mutation in TSHR.18,61 Leu6.40 is located near the cyto-
plasmic end of helix VI. Its substitution by Phe, which is a
generally conservative change, is accompanied by an in-
crease in size. Modeling shows that the newly introduced
Phe clashes with surrounding side chains in any possible
rotameric conformation (two representative conformations
are shown in Fig. 2D), suggesting that Phe physically pushed
the helices III, V, VI and VII apart from each other. Ultimately
this would lead to an opening of the G protein binding cavity.
The conservative substitution of Ala6.34 with several other
hydrophobic amino acids, such as Ile, Val or Phe, provides
another example. In GPHR Ala6.34, located at the cyto-
plasmic tip of helix VI (right where the action happens),
forms a hydrophobic interaction with Ile5.61, contributing
to the tight packing within the helical bundle. Increasing the
size of Ala6.34 probably disrupts the tight packing, resulting
in the opening of the helical bundle.62
3. Several mutations increasing basal activity introduce
an alteration in charge, either a change from negative to
positive or from negative to neutral. Generally, charged
side chains within the helical bundle are likely involved in
electrostatic interactions. Therefore, mutating the side
chain breaks these interactions, releasing a constraint,
Figure 2 Mutational alteration of GPCR basal activity. A. GPCR activation is mediated by conserved structural elements. The
conserved CWxY motif and the residues 3.28 and 3.32, within the ligand binding pocket function as triggers, inducing conforma-
tional changes after ligand binding. These changes include rotameric rearrangements in the D/ERY motif in helix III and the NPxxY
motif in helix VII, which stabilize the active conformation. Mutations affecting any of these essential elements are believed to alter
GPCR activation. B. Mutations increasing basal activity. The residues mutated in at least two receptors are shown in green on the
inactive structure of b2AR (left, side view; right, top view, as seen from the extracellular side; ECL2 helix was deleted for better
visualization). C,D,E. Depending on the change in chemical properties introduced by the substituting amino acid, we propose three
mechanisms, by which the mutation increases basal activity. C. Mutation of Ile2.43 to Thr2.43 decreases hydrophobicity, thereby
weakening the tight helical packing. D. Introduction of Phe at position 6.40 results in physical clashes with surrounding residues and
therefore probably leads to conformational changes within the helical bundle. E. Mutation of Asp6.30 to Asn changes the charge. In
other receptors this Asp6.30 was reported to engage in an electrostatic interaction, which is broken by the introduction of Asn. In
the b2AR this interaction rather results in repulsion with a Tyr residue in ICL2. The numbers of trans-membrane helices I-VII are
indicated in gray circles.
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reversal would even result in repulsion between the two
intended interaction partners, creating the force that
pushes helices apart. For example, Asp6.30, located at the
very tip of helix VI, was reported to form an electrostatic
interaction with Arg3.50, thereby constraining the receptor
in the inactive conformation. By neutralizing the negative
charge (Asp to Asn mutation), this constraint is released,
facilitating the transition from inactive to active confor-
mation. In the crystal structure of b2AR Asp6.30 and Arg3.50
do not interact, but the introduction of Asn leads to
repulsion due to Tyr residues within intracellular loop 2,
suggesting an opening of the cavity (Fig. 2E).
Please note that the charge is not always the most
important factor. The actual chemical environment has to
be taken into account. The best example is the residue
D6.44, which is mutated into a variety of different amino
acids in different receptors. Due to its negative charge and
its orientation towards the middle of the bundle, D6.44 was
suggested to be involved in an electrostatic interaction. In
the Drosophila GPHR homolog D6.44 was reported to interact
with N7.49 of the conserved NPxxY motif. This interaction
restrains the receptor in the inactive state. Thus, breaking
this interaction by either decreasing the size of the side
chain or by altering the charge would be expected to causean increase in the basal activity.10 Interestingly, mutation
into Asn, although neutralizing the charge, does not lead to
constitutive activity, suggesting that hydrogen bonding is
the crucial function of D6.44. In any case, D6.44 mutations
invariably lead to constitutive activity.
Several mutations involve more than one of the changes
mentioned above, opening the possibility of combining
several effects. For example, the substitution of Leu3.43 by
Arg within the TSHR63 and the LHCGR64 changes both the
size and the polarity of the residue. Any rotameric
conformation of the introduced Arg requires conforma-
tional adjustments. The introduction of the positive charge
further destabilizes the helical arrangement.
All three scenarios listed above have one thing in com-
mon: they lead to a general destabilization of the receptor,
thereby increasing its flexibility. Interestingly, no mutations
were discovered in positions essential to the common re-
ceptor activation process, such as micro-switches or G-
protein interaction sites. The exception is the GPHR-specific
FTD motif, where mutations of two out of three residues
were found, further emphasizing the importance of this
motif for GPHR activation. The majority of mutations seem
to exert their positive effect on the basal activity, mostly
through general destabilization of the structure, rather than
through mimicking the effects of ligand binding.
118 H. Stoy, V.V. GurevichMutations of very few residues were reported to
decrease or abolish basal activity; they are scattered all
over the receptor structure without a clear pattern, so it is
impossible to suggest a unifying hypothesis regarding the
mechanism(s) of their action.Mutations affecting GPCRs ability to transduce a
signal from the extra- to the intracellular side
The GPCR-G protein interaction
The ability of a GPCR to respond to the presence of a ligand
by signaling of the appropriate strength is essential to any
physiological process. The receptor adopts an active
conformation, which is characterized by the opening of the
cavity at the cytoplasmic side. Cross-linking experiments of
helices III and VI showed this cavity to be essential for G
protein binding and activation.65 Most of the main inter-
action sites between GPCR and G protein are therefore
expected to be located in and around this cavity.
For a long time most of the evidence about the exact
location and composition of this G-protein interaction
surface came from competition, mutagenesis and cross-
linking experiments. Early studies with the 5HT1A receptor
provided evidence for the importance of the intracellular
loops, especially ICL2 for G protein coupling; when
expressed as a separated peptide, ICL2 competes with the
receptor for the Gi protein, inhibiting AC activity.
66 Further
studies identified several residues of importance within or
in close proximity to ICL2, among them the conserved
R3.50 (DRY motif),67 a conserved hydrophobic Leu68 and a
stretch of residues on the junction of ICL2 and helix IV.69 A
number of mutational studies of all three GPHRs also
implicated ICL3, a hydrophobic motif within ICL3 in
particular, in Gs coupling; it remained unclear whether ICL3
was involved in G protein coupling directly or indirectly by
influencing the packing of helices V and VI.67 Cross-linking
studies using MC3R interacting with Gq protein confirmed
the importance of ICL2 and of a hydrophobic residue within
ICL2, and identified additional residues within helix VI and
the cytoplasmic helix VIII.70 Collectively, biochemical
studies point to the cytoplasmic ends of helices III, V and
VI, the intracellular loops 2 and 3 and the intracellular
helix VIII as elements important for G-protein activation.
Despite extensive progress in identifying the GPCR-G pro-
tein interactions by using those biochemical methods (for
an extensive list of residues associated with G-protein
coupling see71), actual crystal structures of GPCRs in
complex with G-proteins were needed to confirm the
evidence.
The crystal structure of rhodopsin in complex with the
key interacting peptide of transducin, the C-terminus of the
a-subunit, identified positions within helices III, V, VI and
VIII as potential G-protein interaction sites. The complex
structure further illustrated the importance of the DRY
motif as a central activation motif.72 In 2011 Rasmussen
et al23 solved the crystal structure of b2AR in complex with
Gs protein, providing further definite evidence of receptor-
G protein interactions. According to this structure the
interaction sites are mainly located at the cytoplasmic tips
of helices V and VI and within the second intracellular loop
(ICL2) of the receptor, forming a 1,276 A2 interface.Interestingly, the receptor directly interacts only with Gas,
while Gb appears to function in positioning and stabilizing
the Gas N-terminal a helix. Some of the extensive inter-
molecular interactions between b2AR and Gas can be
identified. As predicted by biochemical studies, ICL2 ap-
pears to interact with Gas via hydrophobic contacts. F139 is
buried within a hydrophobic pocket formed by Gas. A
similar interaction was earlier reported in studies using the
Hm1R68 and the MC3R.70 The exact position and orientation
of ICL2 is stabilized by an intramolecular interaction with
the Asp3.49 of the DRY motif within helix III. The DRY motif
is further involved in a direct interaction with Gas; the
complex structure shows that Arg3.50 packs against Tyr 391
of Gas. Both ICL2 and the DRY motif appear to be crucial for
Gas activation.
Venkatakrishnan et al20 compared the residues identi-
fied in both structures and defined a common G protein
interface, consisting of residues at the cytoplasmic tips of
helices III, V and VI and within ICL2. We will refer to this
common interface when comparing mutations to essential
G protein interaction residues.
We would like to mention that very little is known
about G-protein selectivity. The attempts to define spe-
cific signature sequences within the putative G protein-
binding site within the receptor were impeded by the
fact that many GPCRs can interact with more than one
type of G-protein. Current thinking is that the spatial
arrangement (secondary and tertiary), i.e., the active
conformation adopted by the receptor in general and
binding interface in particular, rather than the exact
residues in the contact site, determines the selectivity
for G-proteins.23 Most disease-causing mutations were
characterized by determining the cAMP response,
providing only evidence about the interaction with Gs
protein. A full profile of receptor-G protein interaction
defects requires the determination of other downstream
responses as well.
Incomplete information impedes a reliable judgment of
the signaling ability of the receptor
When analyzing disease-causing mutants for their ability to
respond to ligand, there are several parameters to be taken
into account: 1. The maximum response can generally
reflect both the cell surface expression and the ability to
respond to the presence of the ligand. We therefore
consider a decrease in maximum response despite un-
changed cell surface expression as an indication of defec-
tive transduction ability. 2. The EC50 value by itself does
not necessarily provide a clear answer about the receptor
ability to respond, since both binding issues and signaling
issues are reflected in the EC50 value. 3. The efficacy
eliminates this dual-dependency, by combining the EC50
and the binding affinity; mathematically the efficacy can be
presented as the ratio of binding affinity (KD) to EC50. While
the KD value is independent of the receptor number, the
EC50 decreases with increased cell surface expression. Both
parameters, therefore, need to be determined in the same
experimental setup. For a reliable analysis of a mutant’s
ability to respond to a signal, the cell surface expression,
the maximum response, the EC50 and the KD value need to
be determined. This extensive characterization has only
been done for a few receptor mutants. Therefore, we will
Mutations in GPCRs 119focus on the mutations that show a decreased or increased
maximum response despite normal cell surface expression.
Interestingly, most disease-associated mutations
decrease, rather than increase the ability to respond to a
ligand (Table 2). To our knowledge A6.34V, found in the
TSHR is the only mutation reported to increase maximum
response. Since this mutation also shows increased binding
affinity, it is unclear to which extend the increase in
signaling ability leads to the phenotype of general GOF.
The mutations causing a decrease in maximum response,
visualized in the active conformation of b2AR, (Fig. 3B) are
scattered all over the receptor structure. We want to
stress, that there is only one mutation, which occurred in
multiple receptors. Depending on the location of the mu-
tation we propose two hypotheses how those mutations
influence receptor responsiveness:
1. By affecting the residues in and around the G protein-
binding interface, a mutation can directly influence the
affinity of the receptor for the G protein. Indeed, mutations
of five residues within close proximity of the C-terminal Gas
helix have been reported (Fig. 3C). Of those five residues,
positions 3.50, 3.53 and 6.36 belong to the common
G protein-binding interface. Arg3.50 as the key residue of
G protein activation is directly interacting with the C-ter-
minal Gas helix. Mutation to His in the V2R was found to
decrease activation of adenylyl cyclase due to impaired
G protein coupling.73 Interestingly, this residue was also
found to be substituted by Cys and Leu in the V2R, but aFigure 3 Mutations alter the ability of the receptor to transduce
interaction are shown on the structure of active b2AR in complex w
dark gray). They include several residues within the cytoplasmic c
phobic interaction with a number of residues of Ga Ras-like domai
GPCR-G protein coupling and thus transduction ability. B. Mutatio
receptor expression, are shown on the active structure of b2AR. D
different mechanisms of its action. Residues located within the cen
are expected to alter overall receptor conformational equilibrium;
binding interface (light red) are expected to directly alter the GPCR
the perspective was changed slightly for better visualization. The
circles.comprehensive analysis of these mutants is not available so
far. Both residues Thr3.53 and Arg6.36 point towards the
cavity; any change in size or charge at these positions might
lead to clashes with Tyr391 and Leu393 of the C terminal
helix of Gas, respectively. Position 7.55 was not reported to
be directly involved in G protein activation. Characteriza-
tion of this LHCGR mutant revealed a decrease in maximum
response that could not be explained by the decrease in
cell surface expression.74 We therefore hypothesize that its
orientation towards the cavity might lead to a physical
clash between the newly introduced residue and the C-
terminal helix of Gas. Again we want the reader to keep in
mind that the orientation of this residue within the LHCGR
could be completely different and therefore cause its
defect via a different mechanism.
2. To interact with a G protein, the receptor has to be
able to adopt an active conformation, characterized by the
cytoplasmic opening of the G protein-binding cavity. A
mutation can alter receptor structure and thereby interfere
with the opening of the cavity, while leaving binding af-
finity for the ligand unchanged. We suspect that most of the
mutations, located in the central cluster or in the cluster on
the interface of helices I and II work via this mechanism
(Fig. 3C). A very clear example is Pro7.50, which is
responsible for the kink towards the cytoplasmic side of
helix VII. In the V2R this residue is mutated to a Ser,75
altering the structure of helix VII. Although helix VII has
not been considered essential for G protein activation, thisthe signal. A. Receptor residues essential for GPCR-G protein
ith the Gs protein (Ras-like domain of Ga-subunit is shown in
avity (turquois), and the Phe139, which is engaged in a hydro-
n. Mutations of any of these residues can be expected to alter
ns, altering maximum response along with normal cell surface
epending on the localization of the mutation, we propose two
ter or far from the cytoplasmic site of the receptor (dark red)
residues located at or within close proximity to the G protein-
-G protein interaction. For a detailed view of those residues (C)
numbers of trans-membrane helices I-VII are indicated in gray
Figure 4 The effect of GPCR mutations on agonist binding affinity. Most class A GPCRs have a cavity on the extracellular side,
which in most cases functions as a ligand-binding pocket. A. To visualize this cavity, we highlighted all residues within a 5A distance
from the agonist (left panel, side view; right panel, top view from the extracellular side). B. A common ligand-binding pocket (as
defined by Venkatakrishnan et al (2013)20), consisting of residues involved in ligand binding in several GPCR subtypes, is located at
the bottom of this cavity. Mutations of any of the residues lining this pocket can be expected to change ligand binding affinity. C, D.
Mutations associated with increased or decreased agonist affinity are shown on the inactive structure of b2AR. C. Mutations
increasing agonist affinity of any receptor are mostly located on the interfaces of helices III, V, VI, VII. Two residues belong to the
common ligand-binding pocket (right panel, detailed view from the extracellular side). D. Mutations decreasing agonist affinity of
any receptor are mostly located towards the extracellular side (right panel, detailed view from the extracellular side) or in a
cluster on the interface of helices I and VII near the cytoplasmic site. The only position (Ile3.43) where mutations were reported to
increase or decrease agonist affinity, depending on the substituting amino acid, is shown in orange on the active structure of b2AR.
The numbers of trans-membrane helices I-VII are indicated in gray circles.
120 H. Stoy, V.V. Gurevichstructural change could have an effect on the formation of
the G protein-binding cavity and thereby decrease G pro-
tein activation. Interestingly, A6.59, located close to the
binding pocket, was found mutated to Pro in the LHCGR,
leading to a decrease in cAMP response, likely due to a
defect in coupling. At the same time the mutant demon-
strates wild type binding affinity.76 The newly introduced
Pro is expected to induce structural changes, which despite
its general localization close to the binding pocket more
likely influences the general organization of the trans-
membrane domain, than ligand binding.
It appears that the majority of GPCR mutations exert
their effects by causing general structural rearrangements
in receptors, rather than by affecting key residues
responsible for ligand or G protein interactions. In addition
to the residues discussed above, mutations of a number of
residues within the second and third intracellular loop were
found to decrease transduction ability, in agreement with
the structural and biochemical experimental results.Mutational alterations of GPCR-ligand interactions
The ligand binding pocket
In a physiological context ligand recognition by a cognate
receptor is a crucial event, both in terms of specificity andaffinity. Both parameters are determined by the interface
between ligand and receptor, with a specific structure and
composition, and can therefore be influenced by mutations.
Although different class A GPCRs bind ligands with
various structures, there appears to be a consensus ligand-
binding pocket, consisting of residues essential to general
receptor-ligand contact. Interestingly, this ligand-binding
pocket is buried deeply within the trans-membrane domain
(Fig. 4B), leaving the extracellular loops with the important
role of modulating accessibility. The consensus ligand
binding pocket, as defined by comparison of different
crystal structures, is lined by residues in helices III, VI and
VII.20 It can be expected that additional residues, specific
for different GPCRs, further shape the ligand-binding
pocket (an example is shown in Fig. 4A for the b2AR).
Collectively, common and specific residues determine the
size, shape and electrostatic properties of the ligand-
binding pocket and thereby create specificity.
The GPHRs represent a special case in terms of ligand
binding. Their large extracellular domain (ECD) is respon-
sible for specific ligand binding with high affinity. In all
three GPHRs the ECD consists of a horseshoe-shaped
leucine-rich repeat (LRR) domain and a Cys rich hinge
domain, connecting the ECD to the trans-membrane
domain. The crystal structure of the FSHR ECD in complex
with FSH not only provided evidence for the mode of
Mutations in GPCRs 121hormone binding77 but also suggested the involvement of
this domain in receptor activation.78
Although both regions appear to contact the hormone
directly, the LRR domain constitutes the primary, high-
affinity binding site. Mutagenesis experiments suggest a
number of non-conserved residues within the inner concave
surface of the LRR domain to be important for recognition
specificity.10 This initial binding leads to conformational
changes in the hormone, creating new binding sites for in-
teractions with the hinge region. Among those newly
generated binding sites is a pocket for a sulfated Tyr (sTyr),
located within the hinge region.78 In case of GPHRs, this
sTyr has been shown to be essential for hormone binding
and receptor activation.79 The hinge region has a distinct
structure, stabilized by a number of disulfide bonds. Part of
this structure is a hairpin loop, which is normally positioned
near the extracellular loops, and functions as a tethered
inverse agonist, inhibiting receptor basal activity.80 By
drawing the sulfated Tyr into its binding pocket, the hor-
mone is believed to lift the hairpin loop up, thereby
releasing this inhibitory effect.81 This lifting motion is
converted into a structural change within helix I, which is
expected to lead to similar overall changes within the
trans-membrane region as seen for other GPCRs. This pro-
posed mechanism also implies that the hormone itself
never contacts a ligand-binding pocket within the trans-
membrane domain, in contrast to what is generally
believed for other class A GPCRs. Little is known about how
the hinge region exerts its inhibitory effect on the receptor.
One possible explanation is that it contacts residues within
the ligand-binding pocket, thereby stabilizing the receptor
in inactive state. Contacts with extracellular loops rather
suggest an allosteric mode of inhibition.
Potential mechanisms of mutation-induced changes in
ligand affinity
We propose two mechanisms by which a mutation can
affect the affinity for the ligand: 1. Mutations in or in
close proximity to the ligand-binding pocket can either
directly affect ligandereceptor interactions or alter the
structure of the ligand-binding pocket to change the
binding affinity. Mutations exerting their effect in this way
are expected in different areas for the GPHR and for the
prototypical class A GPCRs (e.g., MC4R and V2R). For the
classical GPCRs we would expect those mutations within
the common ligand-binding pocket, for GPHRs we would
expect mutations within the extracellular loops and the
ECD itself. 2. A second, and more general way to influence
ligand-binding affinity is to alter the conformational
equilibrium of the receptor. It was shown that the active
receptor binds agonists with a much higher affinity than
the inactive receptor.82 By rendering the receptor
more active, or in other words by increasing basal activ-
ity, a mutation can at the same time increase agonist
affinity.
Mutations altering the affinity for ligands are located in
two separate areas and exert their effects via two
different mechanisms
Mutations that were reported to increase or decrease the
KD value of the receptor for the corresponding agonist and
were mapped the inactive structure of b2AR. GOF and LOFmutations overlap only in one residue (3.40). With this
exception, the phenotypes appear to be restricted to
separate areas: GOF mutations, reported for TSHR, LHCGR
and MC4R, are mostly located towards the central and
cytoplasmic side, especially along helix VI. Some additional
mutations are located in helices II, III, V and VII, all pointing
inward (Fig. 4C). Due to their central location, most of
these mutations can be expected to exert their effect on
ligand binding affinity by influencing general receptor
flexibility. Indeed, all but one (I7.52T) mutation associated
with increased agonist affinity also show an elevated basal
activity. Interestingly, two of the reported mutations
belong to the common ligand-binding pocket. The first
mutation S3.36R was discovered in the TSHR. Since the TSH
does not contact the common ligand binding pocket of the
TSHR, the mutation S3.36R is expected to exert its effect
via general structural changes increasing receptor flexi-
bility as most of the other mutations. The second mutation,
F6.51S, was reported in the MC4R. The changes, both in size
and polarity, introduced by this mutation appear to be
significant enough to influence the interaction between
MC4R and the cognate agonist MSH. Overall, direct action of
the mutation via changes in ligand-binding pocket is rare. It
appears that most mutations increasing binding affinity
exert their effect in the most effective and general way, by
changing conformational equilibrium. From an evolutionary
perspective, this finding is comprehensible: natural selec-
tion probably perfected the binding pocket, leaving little
room to further enhance binding affinity by manipulating
those residues directly.
LOF mutations (Fig. 4D) are mostly localized near the
extracellular side of the receptor. Three additional residues
are located close to the cytoplasmic opening on the inter-
face of helices VII and I (7.50, 1.49, 1.50). Depending on the
location within the receptors LOF mutations appear to
exert their effect via one of the mechanisms proposed
above. 1. Mutations at positions 2.57, 3.28, 3.40 and 5.39
are in the large cavity, where most ligands bind. All of those
mutations introduce major changes in polarity, size and
charge, thereby altering the properties of the ligand-
binding pocket, likely directly decreasing the ligand affin-
ity. 2. Mutations, which are not directly associated with the
common ligand-binding pocket, appear to exert their effect
via structural modifications. Mutations within the cluster at
the interface of helices I and VII (1.49, 1.50 and 7.50)
possibly decrease the ability of the receptor to adopt an
active conformation, thereby decreasing agonist affinity. A
mutation introducing a proline at position 2.66 at the
junction of helix II and the extracellular loop 1 can also be
expected to introduce structural changes. Its position close
to the extracellular loops suggest that it rather alters the
structure of the extracellular regions, thereby altering
ligand recognition and/or ligand access and ultimately
decreasing ligand binding affinity.
Mutations in only one position (Fig. 4C and D, labeled in
orange) were reported to both reduce and increase binding
affinity, depending on the receptor and the nature of the
replacing amino acid. Residue 3.40 appears to be located at
a key position within the receptor, having the access to the
ligand-binding pocket and at the same time controlling
GPCR structural changes. To judge the exact effect of each
of these mutations, crystal structures are required.
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mutation can also change the specificity of the receptor-
ligand interaction. This phenomenon has been studied for
the FSHR, where hypersensitivity towards hCG leads to
spontaneous ovarian hyper-stimulation syndrome (sOHSS).
The mechanism of broadening receptor specificity varies
depending on the location of the mutation within the re-
ceptor structure. FSHR receptors with mutations within the
transmembrane region in most cases show a dose-
dependent response towards both hCG and TSH and at
the same time display increased basal activity. Vassart
et al10 suggested that these mutations likely lower the
intra-molecular energy barrier to activation, rather than
affect binding affinity as such. In other words, the mutation
alters receptor conformation, thereby increasing the effi-
cacy of hCG and TSH without altering binding affinity. Even
low-affinity ligands can now initiate a significant response.
The only mutation found within the ECD of the FSHR was
responsive towards hCG but not TSH. Both the location and
the very specific defect of the mutation suggest, that it
directly affects the binding affinity of the receptor towards
hCG, turning a low-affinity ligand into a high-affinity ligand.
Interestingly, a mutation with a similar phenotype was
found in TSHR ECD.83Alterations in GPCR cell surface expression as a
major mutation-induced defect
GPCR biogenesis and maturation
In the cell the level of protein is determined by the rates of
biosynthesis and degradation. In the case of GPCRs this
implies the balance between the process of trafficking of
the receptor to the cell surface and the processes of
internalization and degradation. Both factors have to be
taken into account when interpreting alterations in cell
surface expression of disease-causing mutants. In fact,
decreased expression is one of the most common defects,
accounting for almost 70% of V2R mutants.25,27 Importantly,
due to spare receptors the level of cell surface expression
has to be decreased drastically in order to achieve a sig-
nificant change in signaling. Interestingly, only few muta-
tions have been discovered that result in an increased
number of receptors. Since those mutants also have other
defects, such as increased basal activity, the extent to
which increased cell surface expression contributes to the
phenotype is unclear. We will therefore focus on mutants
decreasing cell surface expression. Of the two factors,
faulty trafficking to the cell surface has been studied more
intensively than the effect mutations have on the inter-
nalization rate. Our main focus will therefore be turned
towards the GPCR targeting to the cell surface.
GPCRs, like other transmembrane proteins, are synthe-
sized and folded in the endoplasmatic reticulum (ER), from
where they are exported via the ER-Golgi intermediate
complex (ERGIC), the Golgi apparatus and the trans-Golgi
network (TGN) to the plasma membrane. The process of
protein transport is highly regulated. Much effort has been
invested into investigation of the sequence determinants
controlling the fate of a receptor. Several motifs, mostly
consisting of a certain arrangements of hydrophobic resi-
dues, have been identified both in the C- and the N-termini.While the role of the C-terminal tail as a major regulatory
region for ER export is widely accepted, the role of the N-
terminus in the trafficking process is less clear; several mo-
tifs in this element have been associated with GPCR export
from the Golgi apparatus.84 In addition, the ER provides an
extensive quality control system, sorting out misfolded
proteins and targeting them for proteasomal degradation.
Mutations are thought to interfere with this biogenesis
pathway at two steps. 1. Direct deletion or mutation of ER/
Golgi export signals have been shown to decrease or abolish
cell surface expression.84 It can be expected that mutations
within the C-terminal tail target those motifs, thereby
leading to the retention of the GPCR in the ER. To our
knowledge, there have been no trafficking motifs identified
within the trans-membrane portion of the receptor. We
therefore exclude this mode of action as a possible mecha-
nism exerted by mutations within the trans-membrane
domain. 2. The ER quality control system disposes of any
proteins incompletely folded or misfolded. Mutations can
therefore exert their effect by destabilizing the receptor
and thereby interfering with correct folding. We would
expect these mutations to be located on the helical in-
terfaces, involved in interactions stabilizing the overall
GPCR structure. Venkatakrishnan et al defined a consensus
scaffold, consisting of 24 residues which form an extensive
network of non-covalent interactions (Fig. 5A).20 Remaining
unaffected by receptor activation, this consensus network
probably preserves the structural integrity of a GPCR.
Although there appears to be a certain tolerance for vari-
ability within this network, mutations can be expected to
lead to receptor instability and thus retention in the ER.
Cell surface expression is generally decreased by
mutational destabilization and ER retention of the
receptor
Mutations decreasing cell surface expression are numerous
and appear to affect most parts of the transmembrane
domain. If we focus on mutations observed in at least two
receptors, this decreases the number of mutations and
largely limits them to a cluster between helices VI, VII and
III, and to the interface of helices I and II. Two additional
residues are located within helices IV and V. (Fig. 5B) The
location on the helical interfaces suggests that these mu-
tations would cause helical rearrangements, possibly
leading to receptor instability. Interestingly, 50% of those
residues are also considered part of the consensus scaffold,
further supporting this hypothesis.
Many signaling defects are accompanied by a reduction
in cell surface expression. For mutants displaying an
increased basal activity this reduction appears to be almost
a general characteristic. Defects in signaling and binding
affinity are accompanied by a decreased cell surface
expression in 45% and over 80% of the cases, respectively.
All of those defects are in part associated with increased
receptor instability, making the receptor flexible enough to
show ligand-independent activity. At the same time this
flexibility increases the chance of misfolding, leading to
retention in the ER. We want to emphasize that a reduction
in cell surface expression affects the interpretation of
other defects in terms of comparison between mutants.
Normalization to cell surface expression is a prerequisite
for reliable comparison of the mutants.
Figure 5 Changes in cell surface expression induced by mutations. A. The structural integrity of the GPCR fold is believed to be
maintained by a network of non-covalent inter-helical contacts (described in20), visualized here on the b2AR structure. Disruption
of this network can be expected to result in increased receptor instability. B. Mutations, increasing (green) or decreasing (red)
receptor cell surface expression in at least two different receptors, are shown on the inactive structure of b2AR. A, B. Left panel,
side view; right panel, top view from the extra-cellular side; for the latter the ECL2 helix was removed for better visualization. The
numbers of trans-membrane helices IeVII are indicated in gray circles.
Mutations in GPCRs 123Therapeutic strategies for correcting genetic errors
in GPCRs
Genetic disorders represent medical problem that is argu-
ably the hardest to address. Here we will discuss several
approaches used to counteract signaling imbalances caused
by the molecular errors in GPCRs. As a rule, mutations in
receptors create complex multi-faceted problems, whereas
existing therapies address only some aspects in each case.
There are quite a few human disorders associated with
mutations in different GPCRs (discussed in the previous
section; see also85).
Pharmacological chaperones to increase receptor cell
surface expression
Many mutants reported to show decreased cell surface
expression are indeed functional.86 Therapeutically
speaking, this means that a simple increase in cell surface
expression could re-establish a close to physiological state
and relieve disease symptoms. Several approaches have
been used to increase cell surface expression, many of
them are especially used in the attempt of deorphanizing
GPCR receptors, where sufficient receptor expression in
heterologous cells poses the main challenge.87 One of these
approaches, the applications of so-called pharmacological
chaperones, has shown promise as a therapeutic strategy in
diseases associated with protein misfolding (reviewed
in86,8892). The concept of pharmacological chaperones
(also known as pharmacochaperones or pharmacopherones)
has been studied in vitro, in vivo and clinically for several
different diseases, not limited to GPCRs. Pharmacologicalchaperones function by directly assisting in protein
biogenesis and/or by correcting misfolding of a specific
protein, having the advantage of avoiding disruption of
general proteostasis. To exert their effect, they have to
cross the membrane; the potential chaperone therefore has
to be not only target-specific, but also small in size and
hydrophobic enough to freely diffuse into the cell.
Mechanistically, several modes of action have been
proposed90: pharmacological chaperones can stabilize the
native conformation, compensating for the destabilizing
effect of mutations. Protein stability is generally increased
by intra-molecular interactions, such as hydrogen bonds,
disulfide bonds, and electrostatic interactions. Mutational
disruption of any of these interactions can be rescued by
pharmacological chaperones mimicking them. The
gonadotropin-releasing hormone receptor (GnRHR) mutant
Asp90Lys can be rescued by the application of a pharma-
cological chaperone, which recreates the salt bridge be-
tween Asp98 ad Lys121 to compensate for the change in
charge and resulting disruption of a salt bridge.93 This mode
of action applies only to a very limited number of re-
ceptors. A more general approach is the application of re-
ceptor ligands, both agonists and antagonists, since ligand
binding limits receptor conformational freedom and stabi-
lizes a native conformation. The application of receptor
ligands requires the careful consideration of pharmacolog-
ical parameters. The chaperone should increase folding
efficiency significantly at non-toxic concentrations (low
EC50) and be easily replaceable by physiological concen-
trations of endogenous receptor agonist (low IC50) to ach-
ieve an increase in functionality in addition to the increase
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specifically rescuing MC4R, its high binding affinity towards
misfolded MC4R increases the receptor recovery rate, but
inhibits receptor functionality because the endogenous
agonist has to compete with NBP.94 Pharmacological chap-
erones have also been used to affect protein oligomeriza-
tion either by facilitating the formation or by stabilizing
already formed oligomers.
This approach has been applied to several GPCRs,
among them two of the receptors we described in this
review, the MC4R and the V2R. Mutant MC4R as the cause
of monogenic obesity is the perfect target for pharmaco-
logical chaperones. Several compounds have been identi-
fied in vitro that affect both cell surface expression and
receptor functionality to different extent. Most of these
demonstrated a limited rescue potential and/or a narrow
rescue profile, not qualifying as a general therapeu-
tic.26,94,95 Recently, new MC4R antagonists, Ipsen 5i and
Ipsen 17, were identified, which rescue a broader spec-
trum of MC4R mutants with a high efficiency at concen-
trations as low as 109 and 108 M, respectively.96,97
Functionality was restored in most of the studied cases.
As expected, these chaperones were unable to function-
ally rescue mutants with additional defects, such as
impaired ligand binding ability. The action of pharmaco-
logical chaperones is limited to the cell surface expression.
Several MC4R mutants (e.g., P299H) appear to be resistant
to the stabilizing effect of all pharmacological chaperones
studied to date. The authors suggested that the confor-
mational change introduced by this mutation was too
strong to be complemented.94 So, despite the general
success of the pharmacological chaperones, their rescuing
ability does not apply to every MC4R mutant, killing the
idea of a single compound acting as a universal pharma-
cological chaperone. Thus, these compounds can only be
used in personalized therapeutics. In vivo experiments are
required to demonstrate specificity and pharmacological
potential of these compounds in the treatment of obesity
caused by MC4R mutations.
In contrast to the MC4R chaperones, V2R chaperones
have been studied in vitro and used in clinical trials to treat
XNDI. Two compounds are especially interesting. The non-
peptide V2R specific antagonist SR121463, available as
different salts,98,99 was shown to partially rescue a V2R
mutation responsible for XNDI. In vitro studies revealed a
dramatic increase in cell surface expression and a signifi-
cant increase in receptor function, although full function-
ality could not be restored.100 Comparable data have been
obtained in two additional in vitro studies.101,102 The ac-
tion of the second chaperone, the non-peptide V1aR
antagonist SR49059, has been demonstrated both in vitro
and in vivo.103 Within several hours after application,
SR49095 was able to decrease the urine volume and the
water intake of NDI patients, demonstrating successful
symptom relief. In vitro data provide further evidence that
SR49095 exerts its therapeutic effect by increasing cell
surface expression of otherwise retained V2R mutant.
However, interference with cytochrome P450 metabolic
pathway precluded the clinical application of SR49095.103
Again, several mutants did not respond to the stabilizing
effect of this pharmacological chaperone due to severe
distortion of receptor structure.Compensation by re-engineered proteins
LOF mutations are usually recessive, i.e., the product of
the “good” allele is sufficient to do the job. In contrast,
GOF mutations are dominant and always result in excessive
signaling, causing a problem.7 Inverse agonists, which shift
the equilibrium towards inactive receptor conformations,
can suppress this signaling,104 sometimes even to the point
of restoring the balance. Despite its simplicity, this concept
is hardly implemented yet in GPCR therapeutics.19 A TSHR
specific inverse agonist has been shown in vitro to exert an
inhibitory effect on the basal activity of both WT and four
constitutively active TSHR mutants. Basal activity was
lowered down to 36%e78% of WT.105 In vivo studies and
clinical trials to treat hyperthyroidism, Graves’ Disease and
metastatic thyroid cancer are on their way. Equivalent
compounds for LHCGR and FSHR, both associated with
classical hyper-phenotypes have not been identified yet.
Clinical studies in combination with in vitro experiments
using H2R revealed a possible down-side of inverse agonism
in therapeutics: upregulation of receptor number appears
to compensate for the inhibitory effect, thereby leading to
tolerance observed after chronic treatment.106 In vitro
studies with b2AR and a1B-adrenoreceptor have provided
further evidence that this could be a general problem of
the long-term application of inverse agonists.107,108
G-protein-mediated signaling by most GPCRs is termi-
nated by a conserved two-step mechanism109: active re-
ceptors are phosphorylated by G protein-coupled receptor
kinases (GRKs),110 whereupon the receptor acquires high
affinity for a cognate arrestin.111 The formation of the
arrestin-receptor complex precludes further coupling to G-
proteins,109 and initiates the second, G-protein-indepen-
dent wave of signaling.112,113 This mechanism stops working
when mutations eliminate GRK phosphorylation sites, so
that resulting receptor is perfectly normal in every way, but
its signaling cannot be stopped via GRK phosphorylation and
subsequent arrestin binding.114,115 This type of GOF muta-
tion is also dominant: the presence of even a small amount
of inactivation-deficient receptor results in excessive
signaling.116 WT arrestins preferentially bind active phos-
phorylated receptors.117 Extensive mutagenesis stud-
ies118e123 supported by X-ray crystallography of all four
vertebrate arrestin subtypes124e127 revealed the mechanism
of function of arrestin sensor that detects receptor-
attached phosphates and yielded a number of “enhanced”
phosphorylation-independent mutants that bind with high
affinity even unphosphorylated active receptors and quench
their signaling via G proteins.122,123,128 The ability of
enhanced mutant of visual arrestin-1 to compensate for
defects of rhodopsin phosphorylation in rod photoreceptors
in vivo in genetically modified mice was recently tested.129
The good news was that this compensational approach to
gene therapy of GOF mutations works: the expression of
enhanced arrestin-1 in photoreceptors where rhodopsin was
not phosphorylated due to the absence of rhodopsin kinase
improved retinal morphology, prolonged photoreceptor
survival, and improved their functional performance.129
However, the rate of signaling shutoff in “compensated”
rods was slower than in WT animals, suggesting that more
potent phosphorylation-independent versions of arrestin-1
are needed.129 New arrestin-1 mutants specifically
designed to target unphosphorylated rhodopsin were
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tested in vivo.
Visual signaling is characterized by much faster kinetics
and is generally significantly more demanding than any
other GPCR-driven system. So, if enhanced mutants
partially compensate for defects of rhodopsin phosphory-
lation, they are likely to work much better in suppressing
excessive signaling by non-visual GPCRs. Due to conserva-
tion of the overall arrestin fold,124e127 mutations homolo-
gous to those that make visual arrestin-1 phosphorylation-
independent have the same effect on non-visual arrest-
ins.122,123,128,131 Thus, enhanced versions of non-visual
arrestins can be expected to be effective suppressors of
excessive signaling by GPCRs with GOF mutations. However,
there is a problem: both arrestin-2 and -3 are fairly pro-
miscuous, interacting with many GPCRs.132,133 As most cells
express numerous GPCR subtypes, the introduction of an
enhanced non-visual arrestin would suppress signaling not
only by GOF mutant that needs to be targeted, but also by
all the other GPCRs in the same cell, likely producing un-
wanted side effects. Arrestin-1 is naturally selective for
rhodopsin,134 demonstrating the feasibility of constructing
receptor-specific arrestins. Subsequent studies established
that relatively few exposed residues on the extensive
receptor-binding surface determine receptor specificity of
arrestins.135 Indeed, substitutions of these “receptor-
discriminator” residues in bovine arrestin-3 with those
found in homologous positions in arrestins from various
species112 yielded mutants of this most promiscuous non-
visual subtype with greatly increased receptor specificity,
with up to 60-fold preference for some receptors over
others.136,137 These results suggest that non-visual arrestins
selectively targeting individual GPCRs with GOF can be
constructed and used for compensational therapy.138
Genome editing
Recently developed methods of targeting selected genomic
sequences in vivo made it possible to correct the errors in
genes, thereby eliminating the very cause of disorders
associated with receptor mutations. Three types of tools
can be used to this end: Zinc finger nucleases (ZFNs),
TALENs, and CRISPR/Cas system (recently reviewed in
detail in139,140). The use of each of these tools, just like the
use of compensational approach described above, requires
the equivalent of gene therapy: the delivery of DNA
encoding appropriate tools to particular cells in the body.
Recent success of three clinical trials of Leber’s congenital
amaurosis, a blinding disorder that is caused by LOF mu-
tations in retinal pigment epithelium-specific 65 kDa pro-
tein (RPE65), which lead to a deficit of the 11-cis-retinal
necessary for photopigment regeneration, demonstrated
the feasibility of this approach.141144 Obviously, LOF, not
GOF mutation was corrected in this case, and gene delivery
to a fraction of RPE cells was sufficient to restore the
supply of 11-cis-retinal to photoreceptors. If correction in
all or even the majority of cells expressing “offending”
mutant is necessary, it cannot be achieved using current
viral or non-viral delivery vehicles. Luckily, it appears that
this is not going to be required in most cases. One recent
study used lentiviral delivery of GRK6 gene to strengthen
homologous desensitization machinery in the striatum to
suppress dyskinesia, a devastating side effect of L-DOPAtherapy, which is the most effective in Parkinson’s dis-
ease.145 It turned out that in both rats and monkeys
increased expression of GRK6 in a fraction of striatal neu-
rons had a clear beneficial effect.145 Although a few
existing successes may not tell the whole story, it appears
likely that in most disorders correction of the signaling in a
fraction of affected cells might be sufficient for thera-
peutic outcome.
Every method of in vivo manipulation of genome and
protein expression has its drawbacks. Replacement of LOF
mutant with normal allele via gene delivery can only be
successful when the expression in a fraction of affected
cells is sufficient, as there are no methods that guarantee
gene delivery to the majority of targeted cells. The same is
true for compensational approach: the signaling can be
rebalanced only in cells that received cDNAs encoding re-
engineered proteins, so many cells will remain uncorrec-
ted. Another danger of re-engineered signaling proteins is
that in many cases more than one function might be
affected, even though the mutant was designed to change
just the desired one. We do not know enough about most
proteins to be sure that only the targeted function is
changed. A good example is arrestin-3 where the residues
responsible for GPCR binding were replaced with alanines.
As expected, it lost the ability to bind GPCRs.135 Unex-
pectedly it was found that, although this mutant binds all
kinases in the ASK1-MKK4-JNK3 pathway, like parental
arrestin-3 or even better, in contrast to WT protein it does
not facilitate JNK3 activation.146 Thus, even though JNK3
and upstream kinases interact with the other side of the
arrestin-3 molecule than the receptor,147 mutations on the
receptor-binding side affect their binding. This example
illustrates the point that creating a mutant protein where
only one function is changed is not an easy task.
Targeted regulation of gene expression
Importantly, the tools that enable gene targeting and repair
can also be used to selectively increase or suppress the
expression of a normal protein. CRISPR can enhance the
transcription of endogenous genes when inactive mutant
Cas9 and guide RNA for targeting transcription activation
elements to specific promoters is used.148e151 Similarly,
catalytically inactive Cas9 targeted to promoters can
repress transcription.148e151Conclusions and future prospects
Safety is an important consideration for any therapeutic
approach. Gene delivery is necessary for gene therapy to
correct LOF (replacement) and GOF (compensational) mu-
tations, as well as to repair mutations using ZFNs, TALENs,
or CRISPR-Cas. Thus, any side effects associated with viral
or non-viral methods of targeted gene delivery are the
same in all these cases. From the prospective of safety,
modified catalytically inactive Cas targeted to particular
sites in the genome to increase or suppress transcription, as
well as replacement gene therapy, are probably the least
likely to cause unwanted side effects: the proteins
expressed as the result of gene activation are WT,
“approved” by evolution, and therefore harmless in most
cells. The expression of modified proteins, e.g., necessary
126 H. Stoy, V.V. Gurevichfor compensational gene therapy, is less safe: in many cases
harm can be done by simultaneous changes in functions
that were not expected to be modified. The least safe is
probably genome editing involving the expression of active
nucleases of any kind in vivo: in many cases these con-
structs were found to be cytotoxic, most likely because
they hit unintended places in the genome, despite careful
targeting. In this sense CRISPR-Cas, that targets only one
23-base sequence, is more prone to off-target activity than
ZFNs and TALENs, which use two sequences of similar size
located at a partivcuilar distance from each other.139
Therapeutic use of any approach in all cases would
require careful estimate of potential dangers and bene-
fits.140 It is highly unlikely that “one size fits all” approach
to correcting genetic errors in GPCRs or any other protein
class will be ever developed. The better we understand the
mechanisms underlying disease phenotypes, the more
informed decisions we can make regarding advisability of
each therapeutic strategy.
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